Zhejiang Doer Biologics Co., Ltd. clinical trials
Acquired by Huadong Medicine Co., Ltd., Apr 2021 · source ↗
The registry lists 9 studies whose lead sponsor is Zhejiang Doer Biologics Co., Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Before and after it joined Huadong Medicine Co., Ltd.
- First submitted before Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- 0
- First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- 9
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Zhejiang Doer Biologics Co., Ltd.9 studies
Something wrong with this grouping? Tell us on the Huadong Medicine Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Huadong Medicine Co., Ltd. studies →
- A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney DiseaseNot yet recruitingNCT07848880Phase 2
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaNot yet recruitingNCT07693777Phase 3
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe HypertriglyceridemiaNot yet recruitingNCT07680829Phase 3
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal CancerRecruitingNCT07056777Phase 1/2
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06132828Phase 1
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624CompletedNCT05378893Phase 1
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsActive, not recruitingNCT07024212Phase 2
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid TumorsTerminatedNCT05639153Phase 1
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.
- A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaCompletedNCT06555640Phase 2
Sponsor listed in the registry: Zhejiang Doer Biologics Co., Ltd. · First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd.